Enbrel is a family affair

The announcement by Immunex Corp. of a North American co-promotion agreement with Wyeth-Ayerst Laboratories for Enbrel, IMNX's tumor necrosis factor receptor to treat advanced rheumatoid arthritis, may be more significant for what it says about the future of IMNX than the potential $100 million the biotech company stands to earn from the deal.

In contrast to many biotech funny-money deals, this one has significant milestones that can be achieved fairly rapidly - made

Read the full 723 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers